Vanguard Capital Management’s First Tracks Biotherapeutics TRAX Stock Holding History

Vanguard Capital Management’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.2M	Buy	+1,451,909	New	+$27.1M	﹤0.01%	2238

Other funds holding TRAX

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Capital Management's TRAX Position: Q2 2026 in Review

Vanguard Capital Management opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 1,451,909 shares worth $29.2M. The stake represents ﹤0.01% of the portfolio and ranks #2238 among its holdings.

89 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

Vanguard Capital Management held 1,451,909 shares of First Tracks Biotherapeutics worth $29.2M as of Q2 2026.
First Tracks Biotherapeutics was a new Vanguard Capital Management position in Q2 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2238 holding.
89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.